The Wemedoo Story
Wemedoo's journey in clinical research innovation
Wemedoo has grown by unifying data, simplifying trial operations, and challenging the fragmentation that has long held clinical research back.
About Us
How Wemedoo grew from an idea to a global clinical research partner
Wemedoo was born from the frustration of fragmented clinical systems and the belief that research teams deserve better.
From early work in semantic data modelling to being recognized globally for innovation, our journey reflects years of scientific rigor, technological breakthroughs, and meaningful partnerships. Today, our solution supports research teams across continents, unifying data and driving progress in clinical research for tomorrow.
Our Milestones
Milestones of our journey
From a founding idea rooted in clinical frustration to global recognition, each year marks a decisive step forward.
The founding of Wemedoo
In 2020, Wemedoo was officially founded by Dr. Nikola Cihoric, a radiation oncologist whose daily experience with fragmented systems and inconsistent clinical data workflows revealed a deeper structural problem in research infrastructure.
What began as personal, everyday frustration evolved into a clear mission: to build a unified, semantically structured foundation for clinical research. This marked the formal beginning of Wemedoo as a company committed to transforming how clinical data is structured, connected, and used.
Validating our data model in real clinical settings
The SmartOncology project, supported by the Swiss Cancer Foundation and the University Hospital of Bern, validated Wemedoo's semantic data model in one of Switzerland's most advanced clinical environments.
That same year, Wemedoo established formal operational foundations by achieving ISO 9001 and ISO 27001 certifications, confirming structured quality management and information security practices aligned with global standards.
First client, expanded funding, and international partnerships
We onboarded our first client using oomnia EDC and eTMF. Wemedoo received an Innosuisse innovation grant as part of the SMARAGD radiotherapy project, collaborating with multiple institutions to bring semantic interoperability into real-world clinical practice.
oomnia was selected by the ACROSS Global Alliance as a technology partner, supporting multinational clinical trials within its global CRO network.
Expanding oomnia and achieving regulatory recognition
We introduced oomnia eConsent and ePRO, moving closer to a fully unified clinical trial software. Our solution successfully passed FDA and Swissmedic inspections, demonstrating full audit-readiness and exceptional data integrity.
Scientific excellence and major innovation initiatives
A scientific grant awarded at the World Cancer Congress recognized Wemedoo's work on the Common Data Elements (CDE) approach, validating the scientific foundation of oomnia's data model.
During this period, Wemedoo also advanced multiple AI-driven initiatives, including risk assessment tools, a real-world data project in India using oomnia eSource as a primary EHR, and AI pipelines for evidence generation.
In addition, Wemedoo was named a finalist at the ACDM Awards, acknowledging its contribution to modern clinical data management.
Innovation, AI development, and SCDM recognition
In 2025, we advanced our automation and semantic infrastructure by submitting our AI-driven risk assessment tool for public peer review, initiating development of an automatic CDASH-to-SDTM mapper, and further developing a CDISC-powered, AI-supported protocol builder.
These innovations, alongside the implementation of Agentic AI in clinical operations, contributed to Wemedoo being recognized as one of the SCDM Innovators of the Year 2025.
Get Started
Run clinical trials with a unified clinical trial solution
Today we advance clinical research. Tomorrow, we will challenge clinical practices.
Explore oomniaFrequently asked questions
What problem originally inspired Wemedoo's journey?
Wemedoo was founded to solve structural inefficiencies in clinical research, including fragmented digital systems, inconsistent data, and limited interoperability between clinical, operational, and regulatory workflows.
These systemic limitations made it difficult for research teams to maintain data integrity, generate reliable evidence, and scale clinical studies efficiently. Wemedoo emerged to build a fundamentally different, unified clinical research infrastructure.
How did clinical research challenges shape Wemedoo's early vision?
Clinical trial challenges directly shaped Wemedoo's vision to move beyond isolated software tools and instead establish unified, semantically structured data from the outset.
The company created a single, coherent data foundation capable of supporting regulatory compliance, real-time insights, and future innovation across the entire clinical trial life cycle.
How was Wemedoo's approach validated in real clinical environments?
Wemedoo's approach was validated through direct implementation in real clinical and academic settings, where structured, semantically modelled data was tested under real-world research conditions.
A key milestone was the SmartOncology project at the University Hospital of Bern, supported by the Swiss Cancer Foundation, where Wemedoo's data model was first applied within one of Switzerland's most advanced oncology research settings.
Beyond academic validation, Wemedoo's technology has been deployed in live clinical trials and multinational research collaborations, demonstrating regulatory readiness, data consistency, and operational reliability across diverse clinical workflows.
Wemedoo is ISO 9001 and ISO 27001 certified and has successfully undergone FDA and Swissmedic inspections with no findings. Our clinical trial software complies with ICH-GCP, 21 CFR Part 11, and EU Annex 11, ensuring global standards for data integrity, security, and privacy. FDA validation was demonstrated through real clinical trial execution under regulatory oversight.
What role did academic and hospital partnerships play in Wemedoo's development?
Academic and hospital partnerships played a central role in grounding Wemedoo's technology in real clinical research practice.
Collaboration with leading institutions, including university hospitals and research organizations, enabled continuous testing of Wemedoo's semantic data model within complex clinical workflows. oomnia is provided free of charge for academic use, allowing institutions to implement structured, semantically modelled data without financial barriers.
How did Wemedoo's technology evolve to support modern clinical research?
Founded in 2020 by oncology and clinical data experts, Wemedoo was created in response to fragmented legacy eClinical systems. This evolution led to the development of oomnia, a unified clinical trial software designed to eliminate data silos, standardize data structures, and support scalable, high-integrity research across the full clinical trial lifecycle.
How have global partnerships shaped Wemedoo's journey?
Global partnerships have expanded Wemedoo's unified data approach across diverse research environments and study types.
Through strategic collaborations with technology providers, academic institutions, research organizations, and the ACROSS Global CRO Alliance, Wemedoo enables interoperable workflows, real-time data access, and structured data exchange across complex, multinational clinical trials.
How has Wemedoo been recognized by the clinical research industry?
Wemedoo has received international recognition for its unified clinical trial software, oomnia.
Key recognitions include being named one of the Innovators of the Year by the Society for Clinical Data Management (SCDM), being selected as a technology partner by the ACROSS Global Alliance, and being named Runner Up at the Association for Clinical Data Management (ACDM) Awards 2024 for Team Excellence in the Management of Clinical Data.